Beta 2-adrenoceptor agonists regulate the IL-4-induced phenotypical changes and IgE-dependent functions in normal human monocytes.
The beta 2-adrenoceptor agonists salbutamol and fenoterol were tested for their regulatory effects on human monocyte phenotype and functions, either alone or in combination with interleukin-4 (IL-4). These drugs enhanced in a dose-dependent manner the IL-4-induced membrane and mRNA expression of the low-affinity receptor for immunoglobulin E (IgE) (CD23), as well as the release of its soluble form, sCD23. Salbutamol and fenoterol alone elicited expression of the monomorphic beta 2-chain (CD18) of the leukocyte functional antigen (LFA1) family. This effect appeared to be restricted to CD11b (CR3) and CD11c (gp 150-95), because CD11a (LFA-1 alpha chain) was not modified. beta 2-Adrenoceptor stimulation was also found to potentiate the effect of IL-4 on CD11b, CD11c, and CD18 expression. In contrast, these agents alone did not alter the level of major histocompatibility complex class II and CD14 antigens or modify their respective up- and down-regulation by IL-4. Ligation of CD23 on IL-4-preincubated (CD23+) monocytes with IgE/anti-IgE immune complexes induced the release of free radicals nitric oxide and of the proinflammatory mediators IL-6 and thromboxane B2 (TxB2). Addition of salbutamol, inactive alone, potentiated the generation of superoxide anion and of nitric oxide generation, as well as the production of IL-6 and TxB2 triggered by CD23 ligation. These results indicate that beta 2-adrenoceptor stimulation potentiates in vitro the IL-4-induced phenotypical and functional changes on monocytes and suggest that such an interaction could occur in IgE-dependent immune reactions.
Paul-Eugène
N
N
INSERM U 365, Institut Curie, Paris, France.
Kolb
J P
JP
Damais
C
C
Abadie
A
A
Mencia-Huerta
J M
JM
Braquet
P
P
Bousquet
J
J
Dugas
B
B
D000420:Albuterol / Q000494:pharmacology; D015703:Antigens, CD / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D015152:Blotting, Northern; D002478:Cells, Cultured; D005280:Fenoterol / Q000494:pharmacology; D005455:Fluorescent Antibody Technique; D000949:Histocompatibility Antigens Class II / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007073:Immunoglobulin E / Q000494:pharmacology*; D015847:Interleukin-4 / Q000494:pharmacology*; D015850:Interleukin-6 / Q000378:metabolism; D018950:Lipopolysaccharide Receptors; D016169:Lymphocyte Function-Associated Antigen-1 / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D009000:Monocytes / Q000737:chemistry / Q000166:cytology* / Q000502:physiology*; D010641:Phenotype; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D011943:Receptors, Adrenergic, beta / Q000502:physiology*; D017455:Receptors, IgE / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D013481:Superoxides / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013929:Thromboxane B2 / Q000378:metabolism
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000949:Histocompatibility Antigens Class II; D015850:Interleukin-6; D018950:Lipopolysaccharide Receptors; D016169:Lymphocyte Function-Associated Antigen-1; D012333:RNA, Messenger; D011943:Receptors, Adrenergic, beta; D017455:Receptors, IgE; D013481:Superoxides; D015847:Interleukin-4; D005280:Fenoterol; D007073:Immunoglobulin E; D013929:Thromboxane B2; D013755:Tetradecanoylphorbol Acetate; D000420:Albuterol